Glucosylceramide synthase (UGCG) is a key enzyme that catalyzes the initial glycosylation step in the biosynthesis of glycosphingolipids (GSLs) derived from glucosylceramide. UGCG is closely associated with various cellular processes, including the cell cycle, angiogenesis, multidrug resistance, and pathogen invasion. In this study, a short hairpin RNA (shRNA) library designed to target key genes involved in the sphingolipid metabolic pathway was utilized to elucidate their roles in Pseudorabies Virus (PRV). Those findings confirm a significant association between sphingolipid metabolism and PRV infection. In addition, this study demonstrated that the knockdown UGCG expression or inhibition of its activity significantly suppresses PRV infection. This suppression is accompanied by reduced expression of autophagy-related proteins that are induced by PRV infection, blockade of autophagic flux, and significant activation of the STING signaling pathway induced by PRV infection. Through extensive investigation, this research revealed that inhibition of UGCG affects the expression of lysosome-associated proteins, alters the lysosomal pH, disrupts lysosomal homeostasis, and impedes autophagolysosomal degradation. Additionally, UGCG inhibition influences the conversion of light chain 3-II (LC3-II) and the formation of LC3-STING complexes, negatively regulates the autophagic degradation of STING, and ensures sustained activation of the PRV-induced STING signaling pathway, thereby achieving resistance against PRV infection. Finally, through in vivo evaluation, this study revealed that UGCG inhibitors, Eliglustat hemitartrate and Ibiglustat, hold promise as potential therapeutics for the treatment of PRV infection. In summary, this study preliminarily elucidates the impact of UGCG on PRV infection and its associated molecular mechanisms, suggesting UGCG could serve as a potential novel target for the prevention and treatment of viral diseases such as PRV.
Read full abstract